Semaglutide

Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.

Mechanism of Action

Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control.

Typical Dosage (Research)

Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary.

Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects.

Side Effects & Risks

Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions.

Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2 syndrome. Risk of pancreatitis, gallbladder disease, and potential retinopathy progression in diabetics.

Who Uses Semaglutide

Those seeking significant weight loss, Type 2 diabetics, individuals with obesity-related health conditions.